News | December 27, 2011

ASE Recommendations Help Move 3-D Echo Into Routine Clinical Practice

December 27, 2011 — The January 2012 issue of the Journal of the American Society of Echocardiography (JASE) will feature a new resource for guidance on three-dimensional echocardiography (3-DE). The document, titled The EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography, provides a practical guide on how to acquire analyze and display the various cardiac structures using 3-DE.

The paper also discusses limitations of the technique, as well as current and potential clinical applications of 3-DE and its strengths and weaknesses in those scenarios.

This technique is gaining appreciation in the medical field, as it can be of benefit to patients with valvular heart disease and to more accurately quantify chamber dimension and function. A full understanding of the technical principles of 3-DE, and a systematic approach to image acquisition, display and analysis, is essential to support its integration into routine clinical practice.  

The usefulness of 3-DE has been demonstrated in: (a) the evaluation of cardiac chamber volumes and mass, which avoids geometric assumptions;(b) the assessment of regional left ventricular wall motion and quantification of systolic dyssynchrony; (c) presentation of realistic views of heart valves; (d) volumetric evaluation of regurgitant lesions and shunts with 3-DE color Doppler imaging; and (e) 3-DE stress imaging.

ASE Past President Roberto M. Lang, M.D., FASE, professor of medicine and radiology and director of the cardiac imaging center at the University of Chicago Medical Center, lead author of the document, explains: “While 3-D TTE currently complements routine 2-D in daily clinical practice by providing additional volumetric information, its full complementary potential has not yet been exploited. ASE has provided a practical technical operation document for 3-D TTE and TEE with current standard echocardiography systems and on-cart software.” He adds, “While the details will become obsolete with future systems, those who have started with clinical 3-DE and developed a full understanding of basic terminology should be able to easily follow future evolution of the technique.”

It is important that 3-D images be displayed in uniform manner to facilitate interpretation and comparisons between studies. Lang notes, “In near future, the ability to acquire a single-heartbeat full-volume data set with higher temporal and spatial resolution, and live 3-D color Doppler imaging with a larger angle, should be feasible. All of these will continue to enhance 3-D utility and efficiency in daily clinical practice.”

The January 2012 issue of JASE also includes a number of articles that explore novel applications of 3-DE and further illustrate its clinical relevance. JASE Editor-in-Chief Alan S. Pearlman, M.D., FASE, professor of medicine and director of the echocardiography laboratory at the University of Washington Medical Center, notes: I believe that real-time volumetric imaging using 3-D echocardiography now provides a practical way to measure ventricular volumes and ejection fraction without making any assumptions about chamber geometry, and suspect that one day this imaging method will surpass current 2-D echo imaging, just as 25 years ago 2-D imaging supplanted M-mode echocardiography. Moreover, it is increasingly clear that 3-D echo provides unique views in patients with valvular and congenital heart disorders, and I believe that the clinical use of this technique is likely to grow rapidly.”  

ASE will provide additional education related to this guideline at its annual scientific session in National Harbor, Md., June 29-July 3.  Sessions include 3-D: What Does it Add on June 30, and The Added Value of 3-D Echocardiography: An ASE/EAE Consensus on July 1.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init